At what cumulative anthracycline dose is it recommended to use dexrazoxane for cardioprotection?

Typically considered in patients with anticipated >300 mg/m2 doxorubicin, as has been mentioned, which is most commonly seen in patients with sarcoma or recurrent lymphomas.

Great discussion re: evidence and considerations in this piece in JACC Cardio-Oncology Upshaw et al., PMID 38773999.

In practic...

Dexrazoxane, an iron-chelating agent that scavenges free radicals and reduces ROS generation, has been shown in multiple clinical trials and meta-analyses to decrease the risk of anthracycline-induced heart failure (van Dalen et al., PMID 21678342; Macedo et al., PMID 34396164). Dexrazoxane has been...